| BIOGEN INC. DL -,0005 |
| USA |
| Gesundheit |
| US09062X1037 / 789617 |
| IDP (Frankfurt) / BIIB (NASDAQ) |
| FRA:IDP, ETR:IDP, IDP:GR, NASDAQ:BIIB |
| S&P500 |
| https://www.biogen.com/ |
|
Biogen Inc. is a biotechnology company focused on discovering, developing, and delivering therapies for serious neurological, neurodegenerative, and rare diseases. Biogen’s current portfolio includes treatments for multiple sclerosis, Alzheimer’s..
>Volltext.. |
| 29773.6 Mio. EUR |
| 35970.14 Mio. EUR |
| 8625.44 Mio. EUR |
| 2434.06 Mio. EUR |
| 745.11 Mio. EUR |
| 5.07 EUR |
| 7459.21 Mio. EUR |
| 1147.21 Mio. EUR |
| 2570.12 Mio. EUR |
| 0.33 |
| 3.69% |
| -43.76% |
| - |
| - |
| - |
| - |
| BIOGEN |
| 14.10.26 |
|